Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities:    
Net loss $ (1,963) $ (1,470)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock compensation expense 312 80
Fair value adjustment of common stock warrants (3) (14)
Depreciation 1 4
Provision for doubtful accounts and sales returns allowances - discontinued operations 0 (71)
Amortization of intangible assets 20 0
Loss on disposal of property and equipment 17 51
Change in value of unconsolidated affiliate 0 332
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (57) 75
Accounts payable 2 (237)
Accrued interest on note receivable (17) 0
Accrued expenses and other current liabilities 0 15
Deferred tax liability (336) 0
Current assets and liabilities from discontinued operations 316 (409)
Net cash used in operating activities (1,708) (1,644)
Cash flows from investing activities:    
Acquisition of property and equipment (71) (4)
Net cash received on OEM asset disposition - discontinued operations 0 502
Purchase intangible, goodwill (300) 0
Purchase intangible assets 476 0
Net cash provided by investing activities 105 498
Cash flows from financing activities:    
Net cash provided by financing activities 0 0
Effect of exchange rates on cash and cash equivalents 0 29
Net decrease in cash and cash equivalents (1,603) (1,117)
Cash and cash equivalents at beginning of period 7,820 7,575
Cash and cash equivalents at end of period 6,217 6,458
Supplemental disclosure of non-cash activities:    
Shares issued in CollabRx acquisition 932 0
Note Receivable used as consideration for CollabRx acquisition 300 0
Promissory Note issued in CollabRx acquisition 500 0
Fair value of assets acquired in CollabRx acquisition 2,253 0
Liabilities assumed in CollabRx acquisition $ 997 $ 0